";s:4:"text";s:8768:" Tinea Pedis (Off-label) 250 mg/day PO in single dose or divided q12hr for 2-6 weeks.
Indicated for onychomycosis of the toenail or fingernail owing to dermatophytes (tinea unguium250 mg (1 tablet) PO daily for 6 weeks (fingernail) or 12 weeks (toenail)Renal impairment: Use not recommended if CrCl <50 mL/minHepatic impairment: Use contraindicated in chronic or active liver disease250 mg/day PO in single dose or divided q12hr for 2-6 weeks250 mg/day PO in single dose or divided q12hr for 2-4 weeks500 mg/day PO q12hr for 2-6 weeks; treat for additional 2-4 weeks after resolution of all lesions (resolution may take 3-6 months)Idiosyncratic and symptomatic hepatic injury; more rarely, cases of liver failure, some leading to death or liver transplantSkin and subcutaneous tissue disorders (eg, Stevens-Johnson Syndrome and toxic epidermal necrolysis), drug reaction with eosinophilia and systemic symptoms (DRESS) syndromeSevere neutropenia, thrombocytopenia, agranulocytosis, pancytopenia, anemiaPsoriasiform eruptions or exacerbation of psoriasis, acute generalized exanthematous pustulosis, precipitation and exacerbation of cutaneous and systemic lupus erythematosusMalaise, fatigue, vomiting, arthralgia, myalgia, rhabdomyolysis, reduced visual acuity, visual field defect, hair loss, serum sickness-like reaction, vasculitis, pancreatitis, influenzalike illness, pyrexia, increased blood creatine phosphokinase, photosensitivity reactionsThrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndromeDiscontinue if the following develop: Liver disease, neutropenia (absolute neutrophil count <1000 mcL); skin rash; signs or symptoms of SLEChanges in ocular lens and retina reported; may require discontinuation of therapyPeriodic monitoring of liver function tests is recommendedAsk patients and caregivers to report immediately to healthcare provider any symptoms or signs of persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain or jaundice, dark urine, or pale stools; if these symptoms occur discontinue taking oral terbinafine, and immediately evaluate patient’s liver functionSerious skin/hypersensitivity reactions (eg, Stevens-Johnson Syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms [DRESS] syndrome); manifestations of DRESS syndrome may include cutaneous reaction (eg, rash, exfoliative dermatitis), eosinophilia, and 1 or more organ complications (eg, hepatitis, pneumonitis, nephritis, myocarditis, pericarditis)Due to potential toxicity, confirmation of onychomycosis or dermatomycosis recommendedSmell disturbance reported; discontinue therapy if symptoms occurCYP2D6 inhibitor; may also convert CYP2D6 extensive metabolizers to poor metabolizer statusCases of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, some fatal, reported with terbinafine; discontinue terbinafine if clinical symptoms and laboratory findings consistent with TMA occur; the findings of unexplained thrombocytopenia and anemia should prompt further evaluation and consideration of diagnosis of TMAAvailable data from postmarketing cases in pregnant women are insufficient to evaluate drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomesBecause treatment of onychomycosis can be postponed until after pregnancy is completed, it is recommended that oral terbinafine not be initiated during pregnancyAfter oral administration, terbinafine is present in human milk; however, there are no data on effects on breastfed child or on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy; tablets and any potential adverse effects on breastfed child from therapy or from underlying maternal conditionA: Generally acceptable.
Drugs
If you will need two packets of oral granules with each dose, you may sprinkle the content of both packets on one spoonful or two spoonfuls of non-acidic food. This mixture must be swallowed immediately without chewing. Any child or adolescent (< 18 years) may now receive treatment for a dermatophyte infection that has not responded to topical treatment and oral griseofulvin. The dose of this medicine will be different for different patients. Renal impairment: Use not recommended if CrCl .
Our general interest e-newsletter keeps you up to date on a wide variety of health topics.Take this medicine exactly as directed by your doctor.
The dose is usually 125 mg once a day for 6 weeks.
Your list will be saved and can be edited at any time.The above information is provided for general
Terbinafine tablets may be taken with food or on an empty stomach.
To help clear up your infection completely, it is very important that you keep using this medicine for the full time of treatment, even if your symptoms begin to clear up or you begin to feel better after a few days. Since fungal infections may be very slow to clear up, you may need to take this medicine for several weeks or months. This medicine comes with a Medication Guide and patient instructions. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Read and follow the instructions carefully. Also, it is best to take the doses at the same times every day.
terbinafine in children. Avoid caffeine (coffee, soda, chocolate) while you are using this medicine.
The use of Terbinafine tablets has not been adequately studied in patients with renal impairment and is therefore not recommended in this population (see section 4.4 and section 5.2). If you are using the oral granules, you may sprinkle the contents on a spoonful of pudding or other soft, non-acidic food such as mashed potatoes. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.If you miss a dose of this medicine, take it as soon as possible.
In case of accidental contact with the eyes, rinse eyes thoroughly with running water. Terbinafine may cause caffeine to stay in your body longer than usual. 2002
Similarly, the streamlined authority listing for terbinafine 1% cream now includes the treatment of fungal or yeast infections in this age group. Children 4 years of age and older and weighing less than 25 kg—Dose is based on body weight and must be determined by your doctor.
Ask your doctor if you have any questions. Renal impairment .
Terbinafine tablets are contraindicated for patients with chronic or active hepatic disease (see sections 4.3 and 4.4). Children
Dosage Modifications.
To do so may increase the chance of side effects. In a clinical trial for interdigital tinea pedis, patients receiving oral terbinafine administered for 1 week achieved the same cure rates as those who received 4 weeks of topical clotrimazole 1% cream application (71%).
Contact the applicable plan
Two to 4 weeks of terbinafine treatment is associated with cures rates equal to those for 6 to 8 weeks of griseofulvin treatment.
Tinea Corporis, Tinea Cruris (Off-label) 250 mg/day PO in single dose or divided q12hr for 2-4 weeks